COMPANY-LED DRUG ALERT - RESPREEZA 1,000 MG POWDER AND SOLVENT FOR SOLUTION FOR INFUSION

CSL Behring UK Ltd is recalling the below batches of Respreeza 1,000 mg powder and solvent for solution for infusion (EU/1/15/1006/001) due to a manufacturing deviation that occurred during the filling process. There is a risk of potential microbial contamination due to the failure of the HEPA filters at the manufacturing site and the batches are being recalled as a precautionary measure. This product is only supplied to Pharmacies and/or Hospitals Pharmacies and not to wholesale, via our 3PL partner Alloga UK Ltd

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/company-led-medicines-recall-respreeza-1000-mg-powder-and-solvent-for-solution-for-infusions-eu-slash-1-slash-15-slash-1006-slash-001?utm_medium=email&utm_campaign=govuk-notifications&utm_source=ea5d64be-6beb-4a4b-b8a9-a24edc5aeea8&utm_content=immediately              

Alliance do not stock this product and therefore we are not accepting stock returns.

Company Contact for medical information enquiries

For medical information enquiries, please contact: Jo Heaton (Head of Medical Affairs UK & Ireland, Commercial Operations United Kingdom) CSL Behring UK Ltd by emailing: Jo.Heaton@cslbehring.com

Company Contact for stock enquiries

For stock information enquiries, please contact: Karien Pietersen (Head of Quality) CSL Behring UK Ltd by emailing: Karien.pietersen@cslbehring.com

Service Disruption at Leeds Service Centre

There may be some delays to orders in the Leeds area today, due to the adverse weather conditions. We thank you for your patience and understanding. Please contact Customer Service with any critical requirements.

We’re still here to deliver!

Alliance Healthcare are continuing to support community pharmacy and the NHS in the ongoing fight against COVID-19. It’s important that we ensure our customers know we are still here to deliver!  Please see the attached flyer informing customers of our support.

AmerisourceBergen and Walgreens Boots Alliance announce strategic transaction

AmerisourceBergen Corporation (NYSE: ABC) and Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced strategic agreements under which AmerisourceBergen will acquire the majority of Walgreens Boots Alliance’s Alliance Healthcare businesses for approximately $6.5 billion, comprised of $6.275 billion in cash and 2 million shares of AmerisourceBergen common stock.

AmerisourceBergen’s acquisition of Alliance Healthcare will provide even stronger support for pharmacies and pharmacists across the globe and integrated solutions for pharmaceutical manufacturers.  Walgreens Boots Alliance will be able to increase its focus on expanding its core retail pharmacy businesses, bringing even greater healthcare offerings to patients and customers and further accelerating its progress on its clear set of strategic priorities.

In addition to this transaction, the two companies have agreed to strengthen their strategic partnership by extending and expanding their commercial agreements. Their US distribution agreement will be extended by three years until 2029 and their partnership is being expanded to include a commitment to pursue additional opportunities in sourcing and distribution. Furthermore, Alliance Healthcare UK will remain the distribution partner of Boots until 2031. Together, these agreements are expected to create incremental growth, synergies and efficiencies.

“This strategic agreement with AmerisourceBergen, which we consider to be the world’s leading pharmaceutical wholesaler, is a very positive development for the two companies. This deal will enable significant value creation for both companies and will generate new synergies in addition to those already captured. It is a logical step following the success of our long-term strategic relationship with AmerisourceBergen which has been a strong and trusted partner since 2013,” said Stefano Pessina, Executive Vice Chairman and CEO, Walgreens Boots Alliance. “The transaction will fuel higher future investments to grow and transform our core retail pharmacy and healthcare businesses, and is EPS accretive long-term for Walgreens Boots Alliance.”

“AmerisourceBergen’s vital role in the health system as a key pillar of pharmaceutical innovation and access has been on full display over the past year,” said Steven Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen. “AmerisourceBergen’s financial and strategic position enable this next evolution of enhancing our ability to provide healthcare capabilities across regions and deliver innovative solutions for our upstream and downstream partners. Today’s announcements will expand our reach and solutions in pharmaceutical distribution and add to AmerisourceBergen’s breadth and depth of global manufacturer services, supporting our ability to create differentiated value for all our stakeholders. I look forward to extending and expanding our successful partnership with Walgreens Boots Alliance and welcoming the industry-leading team at Alliance Healthcare to AmerisourceBergen. Together, we will fulfill AmerisourceBergen’s purpose of being united in our responsibility to create healthier futures.”

These announcements between the two global enterprises continue to build on the close partnership and strong foundation that began in 2013. Walgreens Boots Alliance is the largest shareholder of AmerisourceBergen with a stake of nearly 30 percent, and Ornella Barra, Co-Chief Operating Officer, Walgreens Boots Alliance, is a Board Member of AmerisourceBergen.

Further information can be found here

CLASS 2 RECALL - Sodiofolin 50mg/ml Solution for Injection 100mg/2ml

Further to Drug Alert EL (20)A/52 issued on 11 November 2020, medac Pharma LLP is recalling further batches of products following inspection of vials showing hairline damage to the shoulder of the vials. So far, the company has not received any reports of damage for marketed products. However, as this defect may impact on the sterility of the product, the below batches are being recalled as a precautionary measure

MHRA Drug Link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medac-gmbh-t-slash-a-medac-pharma-llp-sodiofolin-50mg-slash-ml-solution-for-injection-100mg-slash-2ml-pl-11587-slash-0005-el-20-a-slash-61?utm_source=84015acc-7689-472c-92fe-db322a8d4537&utm_medium=email&utm_campaign=govuk-notifications&utm_content=immediate

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

For more information or medical information queries, please contact info@medacpharma.co.uk or telephone 01786 458086.

COMPANY-LED DRUG ALERT - INSTANYL 100MCG SINGLE DOSE

Takeda UK Limited is recalling the below batch of Instanyl 100mcg nasal spray solution (EU/1/09/531/015) due to the observation of cracked vials during inspection of the bulk vials and release testing of the finished products. So far, the company has not received any reports of damage for the marketed products. However, due to the low potential for breaking or cracking of the glass vial, which is contained within the plastic actuator casing and a potential risk of microbial contamination, the above batch is being recalled as a precautionary measure

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/company-led-medicines-recall-instanyl-100mcg-nasal-spray-solution-eu-slash-1-slash-09-slash-531-slash-015?utm_medium=email&utm_campaign=govuk-notifications&utm_source=a6ea9305-5a64-4dd6-ae86-912f9bbbe915&utm_content=immediately         

Alliance have not supplied this product and therefore we are not accepting stock returns.

Company Contact for medical information enquiries

For medical information enquiries, please contact: Takeda UK Limited by emailing medinfoemea@takeda.com

Company Contact for stock enquiries

Remaining stock of these batches should be quarantined and returned to Takeda for replacement stock where available.

For stock information enquiries, please contact: Alloga UK by emailing allogaUK.credit.claims@alloga.co.uk

Company-Led drug alert Sodium Chloride 0.9% Solution For Injection

Title:  Company-Led drug alert Sodium Chloride 0.9% Solution For Injection
Class type: Company-Led drug alert

Copy: Fresenius Kabi Ltd is recalling the below batch of Sodium chloride 0.9% Solution for injection (PL 08828/0178) which has a polish labelled ampoule within some of the cartons. As this does not impact the full batch, as a precautionary measure Fresenius Kabi are recalling all packs from this batch number. The outer carton is correct and includes the correct patient information leaflet in the English language. The ampoules are the correct composition and specifications as the UK licensed material, however during manufacture the incorrect ampoule label was used. The affected batch is being recalled and all stock will be replaced by corrected stock from Fresenius Kabi Limited.

The affected products' details are as follows:

Alliance do not stock this product we are not accepting stock returns.

For stock information enquiries, please contact: Fresenius Kabi Ltd customer services centre Email: Customer.Services-UK@Fresenius-Kabi.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

Field Safety Notice - Voluntary Recall Unisex Patterned Sock C1 Med

L&R Medical Uk Ltd (Pway)is recalling the above batches of products as a Field Safety Notice - Voluntary Recall

The affected products' details are as follows:

This is a FSN voluntary recall and Alliance will be accepting stock returns.

For further information, please contact L&R Medical on 08450 606707

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

CLASS 2 RECALL - ZERBAXA 1G/0.5G POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

Merck Sharp & Dohme Limited is recalling the below batches due to the presence of Ralstonia pickettii in recent batches that were manufactured. The below batches are recalled as a precautionary measure whilst investigations into the microbiological quality of the distributed products are underway

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-merck-sharp-and-dohme-limited-zerbaxa-1g-slash-0-dot-5g-powder-for-concentrate-for-solution-for-infusion-el-20-a-slash-60?utm_source=22cd61e8-ab02-4646-bc21-a8c64c009886&utm_medium=email&utm_campaign=govuk-notifications&utm_content=immediate     

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

For stock control enquiries please contact customerservice.msduk@msd.com

Phone number: 01992 452094

For more information or medical information at medicalinformationuk@msd.com

Phone number: 01992 467272

Class 4 Drug Alert (Caution in use only) Co-Careldopa 25mg/100mg tablets

Fairmed Healthcare GmbH has informed us of a discrepancy on the product packaging for some batches. The discrepancy relates to the incorrect spelling of one of the active pharmaceutical ingredients printed on one side of the packs in error.

The affected products' details are as follows:

This is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact:

Fairmed Healthcare GmbH

Dorotheenstraße 48, 22301

Hamburg, Germany, Quality Assurance Department

or via email on QA Manager: l.rozikova@fair-med.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.